Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
17/06/2026 12:02
BRIEF-UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients June 17 (Reuters) - Ucb SA UCB.BR:
ANNOUNCES DATA SHOWING POSITIVE IMPACT OF KYGEVVI IN TK2D PATIENTS
KYGEVVI IS FIRST AND ONLY APPROVED TREATMENT FOR EARLY-ONSET TK2D
KYGEVVI APPROVED BY FDA IN NOV 2025 AND EMA IN MAR 2026
KYGEVVI REDUCED RISK OF DEATH BY 92%-94% IN EARLY-ONSET TK2D PATIENTS
Source text: ID:nPn1mJkKda
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside